Filter
17
Filtered Results: 17
Text search:
GARDP
Global
Acntibiotic
Research
&
Dedvelopment
Partnership
Featured
Recommendations
2
New Publications
2
Language
Document type
Studies & Reports
6
No document type
4
Manuals
2
Strategic & Response Plan
2
Training Material
1
Resource Platforms
1
Guidelines
1
Countries / Regions
Global
2
Asia
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
1
Toolboxes
AMR
12
Global Health Education
3
HIV
1
NTDs
1
GARDP Antimicrobial
recommended
How to address the global crisis in antibiotic research and development.
The report includes a ...
This paper focuses on the Sustainable Development Goals related to poverty, economic growth, inequality, health, food production and the environment. It presents concrete examples of the underlying and complex aspects of ... resistance and its impacts across different Sustainable Development Goals. The aim of this paper is to inform and stimulate discussions on how to further advance the implementation of 2030 Agenda for Sustainable Development, the Global Action Plan on Antimicrobial Resistance, National Action plans on Antimicrobial Resistance, as well as work within all sectors that affect and are affected by antibiotic resistance
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-d...
The Antimicrobial Resistance Benchmark has evaluated for the second time how the most important players in the antibiotic market are addressing the rise of resistance and the global need for appropr...
This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in...
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. Th...
Diese Broschüre möchte dazu beitragen, dass möglichst viele Menschen die Ergebnisse öffentlich finanzierter Forschung nutzen können.
Sepsis contributes significantly to preventable mortality and is the final common pathway to death for severe infectious diseases; it can also arise as a complication of injuries and non-communicable diseases.
Stewardship is defined as “the careful and responsible management of something entrusted to one’s care”. It was originally applied in the health-care setting as a tool for optimizing antimicrobial use, termed “antimicrobial stewardship” (AMS). Stewardship has since be...
Accessed on 04.04.2023
The Drugs for Neglected Diseases initiative (DNDi) is an international
non-profit organization that discovers, develops, and delivers safe,
effective, and affordable treatments for the most neglected patients
Member States have requested WHO policy guidance on how to facilitate the implementation of national AMS activities in an integrated and programmatic approach. This policy guidance responds to that demand from Member States and is anchored in public health guiding principles in the human health sect...
Meeting Report
27–30 June 2017 Manila, Philippines
